Literature DB >> 2332322

Lymphocyte activating factor activity in the serum and cerebrospinal fluid of patients with multiple sclerosis.

D Donati1, P Annunziata, G C Guazzi, D Boraschi, A Tagliabue.   

Abstract

Serum and cerebrospinal fluid (CSF) from patients with multiple sclerosis (MS), patients with other (non-inflammatory) neurological diseases (OND), patients with non-inflammatory non-neurological diseases, and normal controls were assayed for lymphocyte activating factor (LAF) activity by thymocyte costimulation. LAF activity was detected in normal control sera, which did not differ significantly in this respect from MS or OND patient sera. Not were there significant differences by stage of MS (chronic progressive MS, MS in relapse and MS in remission) or between MS patients and the non-inflammatory non-neurological controls. Almost all the CFSs assayed presented lower values than did the corresponding sera. Serum and CSF after fractionation showed no significant increase in LAF activity except in the 2 MS patients in remission. From these data it may be assumed that LAF activity does not necessarily correspond to the clinical phase of MS. The possible role of LAF activity as a marker of MS progression has yet to be determined.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2332322     DOI: 10.1007/bf02334901

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  28 in total

Review 1.  Immunoregulatory T cells in multiple sclerosis: markers and functions.

Authors:  M A Bach
Journal:  Springer Semin Immunopathol       Date:  1985

2.  Unsuspected multiple sclerosis.

Authors:  J J Gilbert; M Sadler
Journal:  Arch Neurol       Date:  1983-09

3.  Interleukin-1 and interleukin-2 production by peripheral blood mononuclear cells in multiple sclerosis patients.

Authors:  K Selmaj; Z Nowak; H Tchórzewski
Journal:  J Neurol Sci       Date:  1988-05       Impact factor: 3.181

4.  Intrathecal production of neopterin in aseptic meningo-encephalitis and multiple sclerosis.

Authors:  S Fredrikson; P Eneroth; H Link
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

5.  Increased plasma interleukin-1 activity in women after ovulation.

Authors:  J G Cannon; C A Dinarello
Journal:  Science       Date:  1985-03-08       Impact factor: 47.728

6.  Interleukin-1 stimulation of astroglial proliferation after brain injury.

Authors:  D Giulian; L B Lachman
Journal:  Science       Date:  1985-04-26       Impact factor: 47.728

7.  Cerebrospinal fluid interleukin 1 like activity during chronic relapsing experimental allergic encephalomyelitis.

Authors:  J A Symons; R V Bundick; A J Suckling; M G Rumsby
Journal:  Clin Exp Immunol       Date:  1987-06       Impact factor: 4.330

8.  The distribution of interleukin-2 receptor bearing lymphocytes in multiple sclerosis: evidence for a key role of activated lymphocytes.

Authors:  A S Bellamy; V L Calder; M Feldmann; A N Davison
Journal:  Clin Exp Immunol       Date:  1985-08       Impact factor: 4.330

9.  Interleukin 1 of the central nervous system is produced by ameboid microglia.

Authors:  D Giulian; T J Baker; L C Shih; L B Lachman
Journal:  J Exp Med       Date:  1986-08-01       Impact factor: 14.307

10.  Potentiation of the T-lymphocyte response to mitogens. I. The responding cell.

Authors:  I Gery; R K Gershon; B H Waksman
Journal:  J Exp Med       Date:  1972-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.